INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $6,650,621 | +1.7% | 601,322 | +13.7% | 1.30% | +1.6% |
| Q4 2022 | $6,541,875 | +346.5% | 528,850 | +403.7% | 1.28% | +263.2% |
| Q3 2022 | $1,465,000 | -96.7% | 105,000 | -73.8% | 0.35% | -92.0% |
| Q1 2019 | $44,744,000 | +122.0% | 400,000 | +100.0% | 4.43% | +73.8% |
| Q4 2018 | $20,158,000 | +56.9% | 200,000 | +100.0% | 2.55% | -44.7% |
| Q1 2016 | $12,847,000 | – | 100,000 | – | 4.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |